2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160040B
    Cobitolimod sodium scrambled negative control 98%
    Cobitolimod sodium scrambled negative control is the sequence scrambled negative control of Cobitolimod sodium.
    Cobitolimod sodium scrambled negative control
  • HY-160040C
    FAM labled Cobitolimod sodium 98%
    FAM labled Cobitolimod sodiumis a FAM labled Cobitolimod sodium.
    FAM labled Cobitolimod sodium
  • HY-160040D
    Cy3 labled Cobitolimod sodium 98%
    Cy3 labled Cobitolimod sodium is a Cy3 labled Cobitolimod sodium.
    Cy3 labled Cobitolimod sodium
  • HY-160073A
    Florensocatib hydrate 2971064-13-6 98%
    Florensocatib hydrate is a DPP1 inhibitor (IC50: 1.6 nM). Florensocatib hydrate has good bioavailability and pharmacokinetic characteristics, and can be used for research of inflammatory disease.
    Florensocatib hydrate
  • HY-160169A
    Necrosis inhibitor 2 (hydrocholide) 98%
    Necrosis inhibitor 2 hydrocholide (Compound B19) is a cell necrosis inhibitor. Necrosis inhibitor 2 hydrocholide can be used to study diseases related to the necrosis pathway, including inflammation, tumors, metabolic diseases and neurodegenerative diseases.
    Necrosis inhibitor 2 (hydrocholide)
  • HY-160216A
    RIPK1-IN-18 sulfate hydrate 2897618-64-1 98%
    RIPK1-IN-18 sulfate hydrate is a potent RIPK1 inhibitor that can be used in autoimmune diseases research (NZ748385A; compound i).
    RIPK1-IN-18 sulfate hydrate
  • HY-160228A
    ORN 02 sodium
    ORN 02 (sodium) is a synthetic single-stranded U-rich RNA and contains 6 repeats of UUAU sequence motif. The AU-rich oligoribonucleotides (ORNs) are able to stimulate TLR8.
    ORN 02 sodium
  • HY-161534A
    Sulfadiazine-OVA
    Sulfadiazine-OVA is a conjugate of Sulfadiazinen (HY-B0273) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    Sulfadiazine-OVA
  • HY-161554A
    Clenbuterol-OVA 98%
    Clenbuterol-OVA is a conjugate of Clenbuterol (HY-101406) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    Clenbuterol-OVA
  • HY-161557A
    Ractopamine-OVA
    Ractopamine-OVA is a conjugate of Ractopamine (HY-113781) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    Ractopamine-OVA
  • HY-162655A
    SLF80821178 hydrochloride 2764877-62-3 98%
    SLF80821178 hydrochloride is an orally active inhibitor for sphingosine-1-phosphate transporter (Spns2), that inhibits the sphingosine-1-phosphate (S1P) release in HeLa with an IC50 of 51 nM. SLF80821178 hydrochloride reduces the circulating lymphocyte without affecting plasma S1P levels in mice.
    SLF80821178 hydrochloride
  • HY-163312S
    Tyk2-IN-18-d5 3018160-63-6 98%
    Tyk2-IN-18-d5 (Compound 13) is the deuterated TYK2 inhibitor, targeting to JH2 domain. Tyk2-IN-18-d5 can be used for the research of inflammatory and autoimmune diseases.
    Tyk2-IN-18-d5
  • HY-163313S
    Tyk2-IN-19-d6 3018160-65-8 98%
    Tyk2-IN-19-d6 (compound 15) is the deuterium labeled Tyk2-IN-19 (HY-163313).
    Tyk2-IN-19-d6
  • HY-163581A
    HBV/HDV-IN-4 hydrochloride 3034059-40-7 98%
    HBV/HDV-IN-4 hydrochloride (Compd 4) is a dual HBV and HDV inhibitor, with an EC50 of <50 nM against HBV.
    HBV/HDV-IN-4 hydrochloride
  • HY-164216A
    (trans)-STAT6-IN-13 98%
    (trans)-STAT6-IN-13 (Compound 95) is a STAT6 inhibitor with IC50 values of ≤300 nM. (trans)-STAT6-IN-13 has weak inhibitory for STAT3. (trans)-STAT6-IN-13 can be used for the researches of cancer, inflammation and immunology.
    (trans)-STAT6-IN-13
  • HY-16561S1
    Resveratrol-13C6 98%
    Resveratrol-13C6 is the 13C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
    Resveratrol-13C6
  • HY-166480S
    (22R)-Budesonide-d8 85128-75-2 98%
    (22R)-Budesonide-d8 ((22R)-BUD-d8) is the deuterium labeled (22R)-Budesonide. (22R)-Budesonide ((22R)-BUD) is the (22R)-enantiomer of Budesonide (HY-13580). (22R)-Budesonide is a non-halogenated glucocorticoid with high local anti-inflammatory activity.
    (22R)-Budesonide-d8
  • HY-166562S
    Levomepromazine-d6 hydrochloride
    Levomepromazine-d6 hydrochloride (Methotrimeprazine-d6 hydrochloride) is the deuterium labeled Levomepromazine hydrochloride. Levomepromazine (Methotrimeprazine) hydrochloride is an orally active antipsychotic compound and Ca2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca2+ levels. Levomepromazine hydrochloride has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine hydrochloride can induce adaptive ER stress and autophagy. In addition, Levomepromazine hydrochloride has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine hydrochloride can be used in the study psychiatric disorders and relieving nausea and vomiting.
    Levomepromazine-d6 hydrochloride
  • HY-166594S
    Deucravacitinib-13C,d3
    Deucravacitinib-13C,d3 is the 13C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis.
    Deucravacitinib-13C,d3
  • HY-167084A
    ASP9133 1047677-07-5
    ASP9133 is a long-acting muscarinic antagonist. ASP9133 inhibits bronchoconstriction. ASP9133 can be used for research of Chronic obstructive pulmonary disease (COPD)[1]/.
    ASP9133
Cat. No. Product Name / Synonyms Application Reactivity